ClinicalTrials.gg
CompletedNCT03512860Updated Dec 14, 2018

Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study

A Phase 1 interventional study of E4/DRSP and VAL in Contraception, sponsored by Estetra. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-14.

Sponsored by Estetra · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The present study is designed to determine the effect of valproic acid (VAL), a UGT2B7 inhibiting drug, on the pharmacokinetics (PK) of estetrol (E4)

Read the detailed description

In the present study, E4/DRSP will be administered alone (Treatment A) and in combination with VAL (Treatment B) following two sequences A-B or B-A.

02

Conditions studied

  • Contraception

Keywords

  • Estetrol
  • Drospirenone
  • Uridine diphosphate glucuronosyltransferase-2B7
  • Drug-drug interaction
  • Valproic acid
03

In context

Lead sponsor

Estetra is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy premenopausal, aged 18-45 years (inclusive) at the time of signing .
  • For subjects who are sexually active and are of : willing to use a highly effective non-hormonal method of from screening until the follow-up assessment, such as (but not limited to): non-hormonal intra-uterine device (copper IUD), bilateral tubal occlusion, vasectomised partner, or sexual abstinence in a heterosexual relationship; this is acceptable when it is in line with the subject's preferred and usual lifestyle. If a subject is usually not sexually active but becomes active, they, with their partner, must comply with the contraceptive requirements as stated earlier.
  • Body weight ≥45 kg, and a between 18.0 and 30.0 kg/m² (inclusive).
  • Negative serum pregnancy test at screening and a negative urine pregnancy test at Day -1.

Exclusion criteria

Exclusion Criteria:

  • The use of:

    • any prescription drugs, including oral or vaginal hormonal , from 28 days prior to first dose administration until study completion;
    • any herbal medication or dietary supplements acting on cytochrome P450 3A4 () functions (i.e., St John's Wort), from 28 days prior to first dose administration until study completion;
    • any over-the-counter medication (including paracetamol or dietary supplements (including vitamins and herbal products ), from 14 days prior to first dose administration until study completion. Limited use (i.e., up to 1200 mg/day) of ibuprofen is allowed;
    • any depot progestogen preparations or an injectable hormonal method of contraception, from 6 months prior to the first dose administration until study completion.
  • History of , serious adverse reaction, or existing to E4, DRSP or VAL, or .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)

    Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.

    Drug: E4/DRSP · Drug: VAL

  • Experimental
    E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)

    Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).

    Drug: E4/DRSP · Drug: VAL

Interventions

  • DrugE4/DRSP

    Drug pages: Estetrol · Drospirenone

    Administered as specified in the treatment arm.

    Also known as: E4 and DRSP combined tablet

  • DrugVAL

    Administered as specified in the treatment arm.

    Also known as: Valproic acid, Depakote®

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of E4

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  2. Area under the plasma concentration versus time curve from time 0 to the last determined concentration (AUC0-tdlc) of E4

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  3. Area under the plasma concentration versus time curve from time 0 to infiny (AUC0-inf) of E4

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

Secondary outcomes

  1. Number of subjects with adverse events as a measure of safety and tolerability

    Time frame: The total study duration (between 50 and 86 days)

  2. Cmax of DRSP

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  3. Cmax of E4-glucuronide metabolites

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  4. AUC0-tdlc of DRSP

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  5. AUC0-tdlc of E4-glucuronide metabolites

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  6. AUC0-inf of DRSP

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

  7. AUC0-inf of E4-glucuronide metabolites

    PK sampling

    Time frame: 0-168 hr post E4/DRSP dose in both periods 1 and 2 of the two sequences A-B and B-A

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Oct 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2018
First posted
May 1, 2018
StartActual
Apr 12, 2018
Primary completionActual
Oct 8, 2018
CompletionActual
Oct 8, 2018
Last update
Dec 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03512860
Lead sponsor
Estetra
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
May 1, 2018
Start date
Apr 12, 2018
Primary completion
Oct 8, 2018
Completion
Oct 8, 2018
Last update
Dec 14, 2018

Study contacts

Sharan Sidhu
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estetrol · Drospirenone · Valine

Start the discussion